Volume | 43,412,876 |
|
|||||
News | - | ||||||
Day High | 0.1947 | Low High |
|||||
Day Low | 0.166 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Jaguar Health Inc | JAGX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.1708 | 0.166 | 0.1947 | 0.18 | 0.17 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
33,660 | 43,412,876 | $ 0.1826563 | $ 7,929,635 | - | 0.0512 - 1.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:31:54 | 25 | $ 0.1776 | USD |
Jaguar Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.14M | 50.76M | - | 9.76M | -41.3M | -0.81 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Jaguar Health News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JAGX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.1621 | 0.1986 | 0.1522 | 0.1723649 | 46,191,214 | 0.0154 | 9.50% |
1 Month | 0.0836 | 0.254 | 0.071 | 0.1470403 | 87,652,057 | 0.0939 | 112.32% |
3 Months | 0.10 | 0.254 | 0.0512 | 0.1183063 | 62,703,230 | 0.0775 | 77.50% |
6 Months | 0.3289 | 0.5144 | 0.0512 | 0.1254682 | 33,668,165 | -0.1514 | -46.03% |
1 Year | 0.479 | 1.22 | 0.0512 | 0.1606955 | 18,267,265 | -0.3015 | -62.94% |
3 Years | 120.75 | 228.00 | 0.0512 | 21.42 | 9,112,344 | -120.57 | -99.85% |
5 Years | 1,186.50 | 1,273.50 | 0.0512 | 70.62 | 9,680,386 | -1,186.32 | -99.99% |
Jaguar Health Description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. |